Furthermore, silencing of RPN2 contributes to reduction of cell proliferation, sphere formation, and invasiveness, and sensitizes osteosarcoma cells to standard chemotherapeutic regimens, thus providing a survival advantage on osteosarcoma-bearing mice. This evidence concerns the gene RPN2 and osteosarcoma.